This effect was possibly because ARID1A deficiency in CRC cells did not reduce the expression of phosphoinositide-3 kinase-interacting protein 1 (PIK3IPI), which is a key target gene for the synthetic lethality of EZH2 inhibitors in ovarian cancer cells (Supplementary Fig. 2f); alternatively, the effect could be due to the activating mutation in PIK3CA in HCT116 cells35. This evidence concerns the gene EZH2 and ovarian carcinoma.